Related Experiment Video

Updated: Jul 4, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Functional polymorphisms of the FAS gene associated with risk of vitiligo in Chinese populations: a case-control

Miao Li1, Dongjie Sun, Chunying Li

  • 1Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Shaanxi, China.

The Journal of Investigative Dermatology
|June 13, 2008
PubMed

Insights

Genetic variations in the FAS gene are linked to an increased risk of developing vitiligo. Specifically, FAS-1377 genotypes AA and AG were associated with higher vitiligo risk in Chinese populations.

Area of Science:

  • Immunogenetics
  • Dermatology
  • Molecular Biology

Background:

  • The FAS/FASLG system is crucial for apoptosis regulation.
  • FAS-FASLG interactions are implicated in melanocyte destruction in autoimmune vitiligo.
  • Functional gene polymorphisms can influence FAS and FASLG transcriptional activity.

Purpose of the Study:

  • To investigate the association between FAS and FASLG gene polymorphisms and vitiligo risk.
  • To evaluate specific genotypes (FAS-1377 G>A, FAS-670 A>G, FASLG-844 T>C) in relation to vitiligo susceptibility.

Main Methods:

  • A hospital-based case-control study involving 750 vitiligo patients and 756 controls.
  • Genotyping of FAS-1377 G>A, FAS-670 A>G, and FASLG-844 T>C polymorphisms.
  • Statistical analysis using adjusted odds ratios (OR) and 95% confidence intervals (CI).

Main Results:

  • The FAS-1377 AA genotype showed a significantly increased risk of vitiligo (OR, 1.49; 95% CI, 1.07-2.08).
  • The FAS-1377 AG genotype also indicated an elevated risk (OR, 1.31; 95% CI, 1.05-1.63) compared to GG.
  • Carriers of 3-4 FAS risk alleles had a substantially higher risk (OR, 2.87; 95% CI, 1.90-4.32) than those with 0-2 variants.

Conclusions:

  • Genetic variants within the FAS gene are associated with altered vitiligo risk.
  • The FAS-1377 polymorphism appears to be a significant genetic factor in vitiligo susceptibility.
  • These findings suggest a role for FAS gene variations in the pathogenesis of vitiligo in Chinese populations.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...